annual EBITDA:
-$409.49M+$135.59M(+24.87%)Summary
- As of today (August 19, 2025), SAGE annual EBITDA is -$409.49 million, with the most recent change of +$135.59 million (+24.87%) on December 31, 2024.
- During the last 3 years, SAGE annual EBITDA has risen by +$47.24 million (+10.34%).
- SAGE annual EBITDA is now -165.35% below its all-time high of $626.60 million, reached on December 31, 2020.
Performance
SAGE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$54.09M+$12.73M(+19.06%)Summary
- As of today (August 19, 2025), SAGE quarterly EBITDA is -$54.09 million, with the most recent change of +$12.73 million (+19.06%) on June 30, 2025.
- Over the past year, SAGE quarterly EBITDA has increased by +$56.89 million (+51.26%).
- SAGE quarterly EBITDA is now -105.55% below its all-time high of $974.50 million, reached on December 31, 2020.
Performance
SAGE quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$302.08M+$56.89M(+15.85%)Summary
- As of today (August 19, 2025), SAGE TTM EBITDA is -$302.08 million, with the most recent change of +$56.89 million (+15.85%) on June 30, 2025.
- Over the past year, SAGE TTM EBITDA has increased by +$146.04 million (+32.59%).
- SAGE TTM EBITDA is now -145.33% below its all-time high of $666.40 million, reached on June 30, 2021.
Performance
SAGE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SAGE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.9% | +51.3% | +32.6% |
| 3 y3 years | +10.3% | +57.8% | +40.4% |
| 5 y5 years | +42.0% | +50.8% | +49.8% |
SAGE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.0% | -29.2% | +69.6% | at high | +54.0% |
| 5 y | 5-year | -165.3% | +42.0% | -105.5% | +69.6% | -145.3% | +54.0% |
| alltime | all time | -165.3% | +42.0% | -105.5% | +71.0% | -145.3% | +57.2% |
SAGE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$54.09M(-19.1%) | -$302.08M(-15.8%) |
| Mar 2025 | - | -$66.83M(-16.7%) | -$358.98M(-12.3%) |
| Dec 2024 | -$409.49M(-24.9%) | -$80.21M(-20.5%) | -$409.49M(+10.3%) |
| Sep 2024 | - | -$100.95M(-9.0%) | -$371.15M(-17.2%) |
| Jun 2024 | - | -$110.99M(-5.4%) | -$448.13M(-11.7%) |
| Mar 2024 | - | -$117.34M(+180.2%) | -$507.26M(-6.9%) |
| Dec 2023 | -$545.07M(-0.1%) | -$41.88M(-76.5%) | -$545.07M(-17.0%) |
| Sep 2023 | - | -$177.92M(+4.6%) | -$656.80M(+5.9%) |
| Jun 2023 | - | -$170.13M(+9.7%) | -$620.09M(+7.3%) |
| Mar 2023 | - | -$155.15M(+1.0%) | -$578.12M(+5.9%) |
| Dec 2022 | -$545.87M(+19.5%) | -$153.61M(+8.8%) | -$545.90M(+5.5%) |
| Sep 2022 | - | -$141.20M(+10.2%) | -$517.44M(+2.1%) |
| Jun 2022 | - | -$128.16M(+4.3%) | -$506.76M(+4.3%) |
| Mar 2022 | - | -$122.92M(-1.8%) | -$485.73M(+6.3%) |
| Dec 2021 | -$456.73M(-172.9%) | -$125.15M(-4.1%) | -$456.73M(-171.0%) |
| Sep 2021 | - | -$130.52M(+21.8%) | $642.92M(-3.5%) |
| Jun 2021 | - | -$107.13M(+14.1%) | $666.40M(+0.4%) |
| Mar 2021 | - | -$93.92M(-109.6%) | $663.63M(+5.9%) |
| Dec 2020 | $626.60M(-188.8%) | $974.50M(-1010.4%) | $626.60M(-220.1%) |
| Sep 2020 | - | -$107.04M(-2.6%) | -$521.87M(-13.2%) |
| Jun 2020 | - | -$109.90M(-16.1%) | -$601.31M(-9.9%) |
| Mar 2020 | - | -$130.96M(-24.7%) | -$667.36M(-5.5%) |
| Dec 2019 | -$705.84M | -$173.97M(-6.7%) | -$705.84M(+1.5%) |
| Sep 2019 | - | -$186.48M(+6.0%) | -$695.73M(+9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$175.95M(+3.8%) | -$637.71M(+31.9%) |
| Mar 2019 | - | -$169.44M(+3.4%) | -$483.66M(+23.4%) |
| Dec 2018 | -$392.10M(+43.8%) | -$163.86M(+27.6%) | -$392.10M(+31.3%) |
| Sep 2018 | - | -$128.46M(+486.5%) | -$298.55M(+22.2%) |
| Jun 2018 | - | -$21.90M(-71.9%) | -$244.32M(-16.7%) |
| Mar 2018 | - | -$77.87M(+10.7%) | -$293.15M(+7.5%) |
| Dec 2017 | -$272.62M(+70.5%) | -$70.31M(-5.3%) | -$272.63M(+5.4%) |
| Sep 2017 | - | -$74.24M(+5.0%) | -$258.61M(+16.3%) |
| Jun 2017 | - | -$70.72M(+23.3%) | -$222.35M(+19.2%) |
| Mar 2017 | - | -$57.35M(+1.9%) | -$186.56M(+16.7%) |
| Dec 2016 | -$159.88M(+69.1%) | -$56.30M(+48.2%) | -$159.88M(+21.0%) |
| Sep 2016 | - | -$37.98M(+8.7%) | -$132.16M(+11.8%) |
| Jun 2016 | - | -$34.93M(+13.9%) | -$118.24M(+9.1%) |
| Mar 2016 | - | -$30.67M(+7.3%) | -$108.33M(+14.6%) |
| Dec 2015 | -$94.53M(+180.0%) | -$28.58M(+18.8%) | -$94.53M(+20.7%) |
| Sep 2015 | - | -$24.05M(-3.9%) | -$78.30M(+22.9%) |
| Jun 2015 | - | -$25.03M(+48.3%) | -$63.70M(+42.0%) |
| Mar 2015 | - | -$16.88M(+36.7%) | -$44.85M(+32.9%) |
| Dec 2014 | -$33.76M(+85.2%) | -$12.35M(+30.5%) | -$33.76M(+24.5%) |
| Sep 2014 | - | -$9.46M(+53.1%) | -$27.11M(+53.6%) |
| Jun 2014 | - | -$6.18M(+6.9%) | -$17.66M(+53.8%) |
| Mar 2014 | - | -$5.78M(+1.4%) | -$11.48M(+26.4%) |
| Dec 2013 | -$18.23M(+90.2%) | -$5.70M(+68.8%) | -$9.08M(+168.8%) |
| Mar 2013 | - | -$3.38M | -$3.38M |
| Dec 2012 | -$9.59M | - | - |
FAQ
- What is Sage Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Sage Therapeutics, Inc.?
- What is Sage Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Sage Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sage Therapeutics, Inc.?
- What is Sage Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Sage Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Sage Therapeutics, Inc.?
- What is Sage Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Sage Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of SAGE is -$409.49M
What is the all time high annual EBITDA for Sage Therapeutics, Inc.?
Sage Therapeutics, Inc. all-time high annual EBITDA is $626.60M
What is Sage Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, SAGE annual EBITDA has changed by +$135.59M (+24.87%)
What is Sage Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of SAGE is -$54.09M
What is the all time high quarterly EBITDA for Sage Therapeutics, Inc.?
Sage Therapeutics, Inc. all-time high quarterly EBITDA is $974.50M
What is Sage Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, SAGE quarterly EBITDA has changed by +$56.89M (+51.26%)
What is Sage Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of SAGE is -$302.08M
What is the all time high TTM EBITDA for Sage Therapeutics, Inc.?
Sage Therapeutics, Inc. all-time high TTM EBITDA is $666.40M
What is Sage Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, SAGE TTM EBITDA has changed by +$146.04M (+32.59%)